Literature DB >> 15135166

A comparison of three NMDA receptor antagonists in the treatment of prolonged status epilepticus.

Weiwei Yen1, John Williamson, Edward H Bertram, Jaideep Kapur.   

Abstract

Three different classes of NMDA receptor antagonists were compared for their effectiveness in terminating prolonged status epilepticus (SE), induced by continuous hippocampal stimulation. Animals were treated after 150 min of SE by intraperitoneal administration of increasing doses of 3-((R,S)-2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid (CPP), MK-801 (dizocilpine), ifenprodil, or saline. EEG recordings were used to determine seizure termination. The first experiment (n = 57 animals) determined the most effective anticonvulsant dose of each agent by determining its ability to terminate SE within the next 300 min. Five control rats treated with normal saline after 150 min of SE continued to exhibit continuous seizures for the next 300 min. All drugs were administered after 150 min of SE. CPP terminated seizures with an ED(50) of 6.4 mg/kg; the maximal effective dose was 15 mg/kg. MK-801 has an ED(50) of 1.4 mg/kg; the maximal effective dose was 2 mg/kg. Ifenprodil was maximally effective at 30 mg/kg. However, an ED(50) could not be calculated. In a subsequent experiment, the NMDA antagonists were compared for their ability to terminate prolonged SE within 60 min of their administration at the most effective dose. MK-801 (2.0 mg/kg) terminated SE in 6 of 10 animals within 60 min, CPP (15 mg/kg) terminated it in 1 of 9 animals; ifenprodil (30 mg/kg) did not terminate it in any of 9 animals treated. In the 300 min following administration, CPP (6/9) and MK-801 (6/10) were equally efficacious in terminating SE but ifenprodil (2/7) was less effective (P = 0.065, chi-square test). The results indicate that the non-competitive NMDA receptor antagonist MK-801 was superior to the competitive antagonist CPP and the pH-sensitive site antagonist ifenprodil, in terminating prolonged experimental SE.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15135166      PMCID: PMC2892717          DOI: 10.1016/j.eplepsyres.2004.03.004

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  46 in total

1.  Motor and electroencephalographic response of refractory experimental status epilepticus in rats to treatment with MK-801, diazepam, or MK-801 plus diazepam.

Authors:  N Y Walton; D M Treiman
Journal:  Brain Res       Date:  1991-07-05       Impact factor: 3.252

2.  Ketamine, phencyclidine, and MK-801 protect against kainic acid-induced seizure-related brain damage.

Authors:  D B Clifford; J W Olney; A M Benz; T A Fuller; C F Zorumski
Journal:  Epilepsia       Date:  1990 Jul-Aug       Impact factor: 5.864

3.  NMDA receptor antagonists and limbic status epilepticus: a comparison with standard anticonvulsants.

Authors:  E H Bertram; E W Lothman
Journal:  Epilepsy Res       Date:  1990-04       Impact factor: 3.045

Review 4.  The biochemical basis and pathophysiology of status epilepticus.

Authors:  E Lothman
Journal:  Neurology       Date:  1990-05       Impact factor: 9.910

5.  Prognostic factors of pentobarbital therapy for refractory generalized status epilepticus.

Authors:  K Yaffe; D H Lowenstein
Journal:  Neurology       Date:  1993-05       Impact factor: 9.910

Review 6.  Systemic effects of generalized convulsive status epilepticus.

Authors:  N Y Walton
Journal:  Epilepsia       Date:  1993       Impact factor: 5.864

7.  Enduring increase in membrane-associated protein kinase C activity in the hippocampal-kindled rat.

Authors:  I Kohira; K Akiyama; A Daigen; S Otsuki
Journal:  Brain Res       Date:  1992-10-09       Impact factor: 3.252

8.  Amygdala kindling-induced seizures selectively impair spatial memory. 1. Behavioral characteristics and effects on hippocampal neuronal protein kinase C isoforms.

Authors:  H J Beldhuis; H G Everts; E A Van der Zee; P G Luiten; B Bohus
Journal:  Hippocampus       Date:  1992-10       Impact factor: 3.899

9.  The competitive NMDA receptor antagonist CGP 40116 protects against status epilepticus-induced neuronal damage.

Authors:  D G Fujikawa; A H Daniels; J S Kim
Journal:  Epilepsy Res       Date:  1994-03       Impact factor: 3.045

10.  Determinants of mortality in status epilepticus.

Authors:  A R Towne; J M Pellock; D Ko; R J DeLorenzo
Journal:  Epilepsia       Date:  1994 Jan-Feb       Impact factor: 5.864

View more
  12 in total

1.  Differential antagonism of tetramethylenedisulfotetramine-induced seizures by agents acting at NMDA and GABA(A) receptors.

Authors:  Michael P Shakarjian; Jana Velíšková; Patric K Stanton; Libor Velíšek
Journal:  Toxicol Appl Pharmacol       Date:  2012-09-27       Impact factor: 4.219

2.  Guidelines for the evaluation and management of status epilepticus.

Authors:  Gretchen M Brophy; Rodney Bell; Jan Claassen; Brian Alldredge; Thomas P Bleck; Tracy Glauser; Suzette M Laroche; James J Riviello; Lori Shutter; Michael R Sperling; David M Treiman; Paul M Vespa
Journal:  Neurocrit Care       Date:  2012-08       Impact factor: 3.210

Review 3.  Why won't it stop? The dynamics of benzodiazepine resistance in status epilepticus.

Authors:  Richard J Burman; Richard E Rosch; Jo M Wilmshurst; Arjune Sen; Georgia Ramantani; Colin J Akerman; Joseph V Raimondo
Journal:  Nat Rev Neurol       Date:  2022-05-10       Impact factor: 44.711

4.  A novel non-transcriptional pathway mediates the proconvulsive effects of interleukin-1beta.

Authors:  Silvia Balosso; Mattia Maroso; Manuel Sanchez-Alavez; Teresa Ravizza; Angelisa Frasca; Tamas Bartfai; Annamaria Vezzani
Journal:  Brain       Date:  2008-10-24       Impact factor: 13.501

5.  Age and activation determines the anticonvulsant effect of ifenprodil in rats.

Authors:  Pavel Mareš
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-05-08       Impact factor: 3.000

6.  Rapid surface accumulation of NMDA receptors increases glutamatergic excitation during status epilepticus.

Authors:  David E Naylor; Hantao Liu; Jerome Niquet; Claude G Wasterlain
Journal:  Neurobiol Dis       Date:  2013-01-08       Impact factor: 5.996

7.  A combination of ketamine and diazepam synergistically controls refractory status epilepticus induced by cholinergic stimulation.

Authors:  Brandon S Martin; Jaideep Kapur
Journal:  Epilepsia       Date:  2007-10-15       Impact factor: 5.864

8.  Treatment of early and late kainic acid-induced status epilepticus with the noncompetitive AMPA receptor antagonist GYKI 52466.

Authors:  Brita Fritsch; Jeffrey J Stott; Joy Joelle Donofrio; Michael A Rogawski
Journal:  Epilepsia       Date:  2009-07-20       Impact factor: 5.864

Review 9.  A Molecular Approach to Epilepsy Management: from Current Therapeutic Methods to Preconditioning Efforts.

Authors:  Elham Amini; Mohsen Rezaei; Norlinah Mohamed Ibrahim; Mojtaba Golpich; Rasoul Ghasemi; Zahurin Mohamed; Azman Ali Raymond; Leila Dargahi; Abolhassan Ahmadiani
Journal:  Mol Neurobiol       Date:  2014-09-09       Impact factor: 5.590

10.  NMDA receptor antagonism with novel indolyl, 2-(1,1-Dimethyl-1,3-dihydro-benzo[e]indol-2-ylidene)-malonaldehyde, reduces seizures duration in a rat model of epilepsy.

Authors:  Hussin A Rothan; Elham Amini; Fadihl L Faraj; Mojtaba Golpich; Teow Chong Teoh; Khadijeh Gholami; Rohana Yusof
Journal:  Sci Rep       Date:  2017-03-30       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.